From BD to Execution: The Most Dangerous Handoff in Pharma

Session details:

• Why the post-signing handoff—not the negotiation—is where most deal value is lost
• The critical deal context that disappears once BD steps back
• How misaligned ownership after signing leads to slow, silent value erosion
• Practical ways to structure handoffs that preserve intent and enable execution
• Who truly owns success after the deal—and how to make that accountability stick